Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03405142 · ClinicalTrials.gov registry record · Phase 2
Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer
A Phase 2 study, sponsored by Eben Rosenthal.
- Completed
- Registry status
- Phase 2
- Development phase
- 3
- Enrollment target
NCT03405142 is a Phase 2 study that has completed, run by Eben Rosenthal. The registered enrollment target is 3 participants.
The verdict
NCT03405142, a Phase 2 study, has completed, sponsored by Eben Rosenthal.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 3 participants
- Enrollment target
Study Summary
This phase 2 trial studies how well panitumumab-IRDye800 works in identifying head and neck cancer that has spread to the lymph nodes in patients with head and neck cancer. Panitumumab-IRDye800 may help surgeons to identify metastatic lymph nodes during surgical removal of the primary tumor and/or lymph nodes of the neck with equal or better accuracy than the current methods.
Interventions
- DRUG Panitumumab-IRDye800
- DRUG Lymphoseek
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2019-08-01 |
| Est. Completion | 2021-04-27 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03405142
The ClinicalTrials.gov registry entry for NCT03405142 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 3 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eben Rosenthal, which has 8 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Panitumumab-IRDye800 is the first listed.
NCT03405142 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03405142 about?
NCT03405142 is a clinical study titled "Panitumumab-IRDye800 Compared to Sentinel Node Biopsy and (Selective) Neck Dissection in Identifying Metastatic Lymph Nodes in Patients With Head&Neck Cancer". This phase 2 trial studies how well panitumumab-IRDye800 works in identifying head and neck cancer that has spread to the lymph nodes in patients with head and neck cancer. Panitumumab-IRDye800 may help surgeons to identify metastatic lymph nodes during surgical removal of the primary tumor and/or l...
What is the current status of trial NCT03405142?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 3 participants. The study started on 2019-08-01. Estimated completion is 2021-04-27.
What interventions are being tested in trial NCT03405142?
The interventions under investigation include: Panitumumab-IRDye800 (DRUG), Lymphoseek (DRUG).
Who is sponsoring clinical trial NCT03405142?
This trial is sponsored by Eben Rosenthal, which has 8 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.